MCID: ISL001
MIFTS: 50

Islet Cell Tumor malady

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Islet Cell Tumor

About this section

Aliases & Descriptions for Islet Cell Tumor:

Name: Islet Cell Tumor 35 11 50 13 68
Well Differentiated Pancreatic Endocrine Tumor 68
Malignant Neoplasm of Endocrine Pancreas 68
Malignant Tumor of Endocrine Pancreas 11
Malignant Pancreatic Endocrine Tumor 11
Pancreatic Endocrine Carcinoma 68
 
Pancreatic Endocrine Neoplasm 11
Endocrine Pancreas Cancer 11
Carcinoma Islet Cell 50
Islet Cell Neoplasm 11
Adenoma, Islet Cell 39
Islet Cell Tumour 11

Classifications:



Summaries for Islet Cell Tumor

About this section
Disease Ontology:11 A pancreatic cancer that is located in the pancreatic islet cells.

MalaCards based summary: Islet Cell Tumor, also known as well differentiated pancreatic endocrine tumor, is related to gastrinoma and pheochromocytoma. An important gene associated with Islet Cell Tumor is SST (Somatostatin), and among its related pathways are Cardiac Progenitor Differentiation and G alpha (s) signalling events. The drug dacarbazine has been mentioned in the context of this disorder. Affiliated tissues include the pancreatic islet cells, pancreas and pancreatic islet, and related mouse phenotypes are digestive/alimentary and cardiovascular system.

Related Diseases for Islet Cell Tumor

About this section

Diseases related to Islet Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 170)
idRelated DiseaseScoreTop Affiliating Genes
1gastrinoma28.8CALCA, CHGA, SST, VIP
2pheochromocytoma28.2CALCA, CHGA, MEN1, SST, VIP
3pancreatic islet cell tumors12.3
4pheochromocytoma-islet cell tumor syndrome12.1
5pancreatic neuroendocrine tumor11.5
6insulinoma11.3
7somatostatinoma11.3
8mahvash disease11.1
9vipoma11.0
10pancreatic endocrine carcinoma10.9
11pancreatitis10.7
12deep corneal vascularisation10.6GAST, SST
13pelvic varices10.5GAST, SST
14focal facial dermal dysplasia10.5CHGA, SST
15pancreatic cystadenocarcinoma10.5GAST, SST
16itch e3 ubiquitin ligase deficiency10.5CHGA, GAST
17giant cell myocarditis10.5CHGA, GAST
1810.5CHGA, SST
19hypoglycemia10.5
20lacrimal passage granuloma10.5GAST, SST
21rectum signet ring adenocarcinoma10.5CHGA, GAST
22brachial plexus lesion10.5INS, SST
23repetitive motion disorders10.4INS, SST
24neuronal ceroid lipofuscinosis10.4INS, SST
25subacute delirium10.4GAST, INS
26central retinal vein occlusion10.4INS, SST
27expressive language disorder10.4CHGA, IGF2
28xanthogranulomatous pyelonephritis10.4CHGA, IGF2
29pituitary adenoma, prolactin-secreting10.4GAST, SST
30mucinous adenocarcinoma10.4CHGA, IGF2
31benign eccrine breast spiradenoma10.4IGF2, INS
32mononeuritis of upper limb10.4INS, SST
33fallopian tube clear cell adenocarcinoma10.4INS, SST
34adult pineal parenchymal tumor10.4CHGA, PTHLH
35motility-related diarrhea10.3SST, VIP
36paranasal sinus cancer, adult10.3CHGA, INS
37small intestine leiomyoma10.3SST, VIP
38nodular tenosynovitis10.3CHGA, PTHLH
39adenosquamous cell lung carcinoma10.3SST, VIP
40fetal methyl mercury syndrome10.3IGF2, INS
41strabismus10.3CALCA, SST
42glioma susceptibility 110.3CHGA, IGF2
43splenic artery aneurysm10.3IGF2, INS
44aggressive systemic mastocytosis10.3GAST, VIP
45spinal chordoma10.3CHGA, GAST, SST
46extragonadal germ cell cancer10.3CHGA, GAST, SST
47adrenal carcinoma10.3INS, SST
48limb-mammary syndrome10.3IGF2, INS
49acanthoma10.3CHGA, GAST, SST
50mixed endometrial stromal and smooth muscle tumor10.3CALCA, CHGA

Graphical network of the top 20 diseases related to Islet Cell Tumor:



Diseases related to islet cell tumor

Symptoms & Phenotypes for Islet Cell Tumor

About this section

MGI Mouse Phenotypes related to Islet Cell Tumor according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.2GAST, IGF2, INS, MEN1, PTHLH, SST
2MP:00053858.1CHGA, IGF2, INS, MEN1, PTHLH, VIP
3MP:00053877.7GAST, IGF2, INS, MEN1, PTHLH, SST
4MP:00053797.7CHGA, GAST, IGF2, INS, MEN1, PTHLH
5MP:00053767.4CHGA, GAST, IGF2, INS, MEN1, PTHLH
6MP:00107687.3CHGA, GAST, IGF2, INS, MEN1, PTHLH
7MP:00053897.2CHGA, IGF2, INS, MEN1, PTHLH, VIP

Drugs & Therapeutics for Islet Cell Tumor

About this section

Drugs for Islet Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 222)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
2
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
3
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
Etanerceptapproved, investigationalPhase 4, Phase 1, Phase 2397185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
5
PancrelipaseapprovedPhase 4, Phase 3, Phase 2, Phase 193553608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
6
SomatostatinapprovedPhase 4, Phase 2, Phase 3, Phase 122938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
7
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
8
ZincapprovedPhase 422317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
9
Lansoprazoleapproved, investigationalPhase 4207103577-45-33883
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
A 65006
A-65006
AB00052388
ABT-006
AC1L1GX8
AG 1749
AG-1749
Abbot Brand of Lansoprazole
Agopton
Almirall Brand of Lansoprazole
Amarin
Aprazol
BIDD:GT0006
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
Bamalite
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
CPD000058469
Compraz
D00355
DB00448
Dakar
DivK1c_000920
EU-0100709
FT-0082011
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
HSDB 7204
Hoechst Brand of Lansoprazole
Hormona Brand of Lansoprazole
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
L 8533
L8533_SIGMA
LS-33080
Lancid
Lanfast
Lanproton
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole [USAN:BAN:INN]
Lansoprazole [Usan:Ban:Inn]
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
Lanston
 
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac-L-8533
Lopac0_000709
MLS-0003247.0001
MLS000069705
MLS000759405
MLS001074170
Mesactol
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
PrevOnco
Prevacid
Prevacid (TN)
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid SoluTab
Prevacid Solutab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
Prevpac
Prezal
Pro Ulco
Promeco
Promeco Brand of Lansoprazole
Promp
Prosogan
S1354_Selleck
SAM001246544
SMR000058469
SPBio_000488
SPBio_002992
SPECTRUM1503926
STK621169
Salvar Brand of Lansoprazole
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
Spectrum_001580
Suprecid
TAK 390MR
TAK-390MR
TAK390MR
TAP Brand of Lansoprazole
TL8000155
Takeda Brand of Lansoprazole
Takepron
Tecnobio Brand of Lansoprazole
UNII-0K5C5T2QPG
Ulpax
Vinas Brand of Lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
lansoprazole
lansoprazole sulphone
lanzoprazole
10Anti-Inflammatory AgentsPhase 4, Phase 1, Phase 210355
11AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211287
12Analgesics, Non-NarcoticPhase 4, Phase 1, Phase 26260
13Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 222776
14Hypoglycemic AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15733
15Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112767
17HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113979
18Angiogenesis Modulating AgentsPhase 4, Phase 2, Phase 3, Phase 14072
19Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112778
20Antirheumatic AgentsPhase 4, Phase 1, Phase 210627
21Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 1, Phase 24295
22Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
23Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
24Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
25Angiogenesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 14143
26Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
27Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
28pancreatinPhase 4, Phase 3, Phase 2, Phase 1935
29pancreatic polypeptidePhase 4, Phase 3, Phase 2, Phase 120
30Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
31
Proton pump inhibitorsPhase 4, Phase 3, Phase 21080
Synonyms:
 
PPIs
32
DexlansoprazolePhase 4207138530-94-6, 103577-45-39578005
Synonyms:
138530-94-6
CHEMBL1201863
CID9578005
D08903
Dexlansoprazole (INN/USAN)
KS-1075
 
Kapidex
MolPort-002-885-834
T 168390
TAK 390
UNII-UYE4T5I70X
ZINC00599734
dexlansoprazole
33Insulin, Globin ZincPhase 4, Phase 24523
34Anti-Ulcer AgentsPhase 4, Phase 3, Phase 21767
35AntacidsPhase 4, Phase 3, Phase 21767
36insulinPhase 4, Phase 24524
37Fluorodeoxyglucose F18Phase 4, Phase 2392
38Trypsin InhibitorsPhase 4122
39HIV Protease InhibitorsPhase 4, Phase 25319
40Serine Proteinase InhibitorsPhase 4850
41
protease inhibitorsPhase 4, Phase 25320
Synonyms:
 
protease inhibitors
42Alpha 1-AntitrypsinPhase 499
43Protein C InhibitorPhase 497
44Protein CPhase 4115
45serineNutraceuticalPhase 4921
46
Exenatideapproved, investigationalPhase 2, Phase 3, Phase 1, Early Phase 1289141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
47
Esomeprazoleapproved, investigationalPhase 3324161796-78-7, 119141-88-74594, 9579578
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(-)-omeprazole
(S)-(-)-Omeprazole
(S)-(−)-omeprazole
(S)-Omeprazole
(S)-omeprazole
(s)-omeprazole
(−)-omeprazole
119141-88-7
119141-89-8
131959-78-9
172964-80-6
193469-77-1
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
326602-80-6
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Axagon
BIDD:GT0020
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CID9568614
CID9579578
CPD000058847
Ceprandal
D00455
D07917
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazol
Esomeprazole
Esomeprazole (INN)
Esomeprazole Sodium
Esomeprazole [INN:BAN]
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
LS-185188
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
 
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-943-880
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium Control
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole (JAN/USP/INN)
Omeprazole S-form
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UNII-N3PA6559FT
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
ZINC04693574
ZINC04693575
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
esomeprazole
esomeprazolum
omeprazole
Ésoméprazole
48
FluorouracilapprovedPhase 3, Phase 2, Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
49
Bevacizumabapproved, investigationalPhase 2, Phase 31968216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
50
LevoleucovorinapprovedPhase 2, Phase 3, Phase 171168538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid

Interventional clinical trials:

(show top 50)    (show all 181)
idNameStatusNCT IDPhase
1Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsUnknown statusNCT00454376Phase 4
2Treatment of Zollinger-Ellison Syndrome With PrevacidCompletedNCT00204373Phase 4
3Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in ChinaRecruitingNCT02842749Phase 4
4Nonfunctional Pancreatic NET and PET ImagingRecruitingNCT02621541Phase 4
5A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsActive, not recruitingNCT01525550Phase 4
6Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine TumorsActive, not recruitingNCT02759718Phase 4
7Anti-inflammatory Therapy to Improve Outcomes After TPIATNot yet recruitingNCT02713997Phase 4
8Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
9Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine TumorsUnknown statusNCT00442533Phase 2, Phase 3
10Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine TumourCompletedNCT00842348Phase 3
11Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursCompletedNCT00353496Phase 3
12Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsCompletedNCT00510068Phase 3
13Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
14Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison SyndromeCompletedNCT00079833Phase 3
15A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related DiseasesCompletedNCT02153398Phase 3
16Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine TumorsRecruitingNCT02589821Phase 3
17A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)RecruitingNCT02288377Phase 2, Phase 3
18Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNETRecruitingNCT02246127Phase 3
19New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet CellsRecruitingNCT02127541Phase 2, Phase 3
20Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic TumorRecruitingNCT02330497Phase 3
21Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the PancreasActive, not recruitingNCT01563133Phase 3
22Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsActive, not recruitingNCT00227617Phase 2, Phase 3
23Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO TreatmentNot yet recruitingNCT02705651Phase 3
24A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell TumorsTerminatedNCT00428597Phase 3
2568-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine TumoursUnknown statusNCT01673906Phase 2
26RAD001 and Erlotinib in Patients With Neuroendocrine TumorsUnknown statusNCT00843531Phase 2
27Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free ImmunosuppressionUnknown statusNCT00566813Phase 1, Phase 2
28Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell CancerCompletedNCT00001228Phase 2
29Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the PancreasCompletedNCT00001165Phase 2
30BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.CompletedNCT01658436Phase 2
31Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01121562Phase 2
32Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsCompletedNCT00602082Phase 2
33Phase II Study of Sunitinib Malate Following Hepatic Artery EmbolizationCompletedNCT00434109Phase 2
34Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
35PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
36Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By SurgeryCompletedNCT00416767Phase 2
37AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2
38Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver MetastasesCompletedNCT00019786Phase 2
39Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2
40Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
41Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2
42Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2
43A Study of IMC-A12 in Islet Cell CancerCompletedNCT00781911Phase 2
44RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedNCT00113360Phase 2
4568Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1, Phase 2
46Pazopanib as Single Agent in Advanced NETsCompletedNCT01280201Phase 2
47The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric AcidCompletedNCT00001191Phase 2
48Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT01169649Phase 2
49KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic TumorsCompletedNCT02250885Phase 2
50Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2

Search NIH Clinical Center for Islet Cell Tumor

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: adenoma, islet cell

Genetic Tests for Islet Cell Tumor

About this section

Anatomical Context for Islet Cell Tumor

About this section

MalaCards organs/tissues related to Islet Cell Tumor:

36
Pancreas, Pancreatic islet, Liver, Kidney, Lung, Endothelial, Breast

FMA organs/tissues related to Islet Cell Tumor:

17
The pancreatic islet cells

Publications for Islet Cell Tumor

About this section

Articles related to Islet Cell Tumor:

(show top 50)    (show all 347)
idTitleAuthorsYear
1
Non-islet cell tumor hypoglycemia caused by intrathoracic solitary fibrous tumor: a case report. (27061182)
2016
2
Non-islet cell tumor hypoglycemia caused by a big insulin-like growth factor II- producing hepatocellular carcinoma:an autopsy case report. (27916774)
2016
3
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. (26487953)
2015
4
The Transformation of a Nonfunctioning Islet Cell Tumor of the Pancreas into a Proinsulinoma under Conditions of Lung Metastasis. (25832942)
2015
5
Multiple hepatocellular adenomas presenting in a male 8 years post-pancreaticoduodenectomy for islet cell tumor of the pancreas. (25810673)
2015
6
Non-Islet Cell Tumor Hypoglycemia Is Caused by Big IGF-II in a Patient with a Carcinosarcoma of the Uterus. (26666605)
2015
7
A 94-year-old man with recurrent hypoglycemia caused by non-islet cell tumor hypoglycemia (NICTH). (25780362)
2014
8
Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia. (25535894)
2014
9
Characterization of a pancreatic islet cell tumor in a polar bear (Ursus maritimus). (25273481)
2014
10
Nonfunctional islet cell tumor of the pancreas in a patient with tuberous sclerosis: a case report with literature review. (24678435)
2014
11
Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. (26425568)
2013
12
Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature. (24616774)
2013
13
GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. (22883930)
2013
14
Nesidioblastosis and Pancreatic Non-functioning Islet Cell Tumor in an Adult with Type 2 Diabetes Mellitus. (24255640)
2013
15
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II. (23545670)
2013
16
Surgical treatment of pancreatic islet cell tumor: report of 44 cases. (24719954)
2013
17
Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review. (24423303)
2013
18
Non-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary. (23512392)
2013
19
Non-Islet Cell Tumor-Induced Hypoglycemia Associated with Macronodular Pulmonary Metastases from Poorly Differentiated Thyroid Carcinoma. (23697382)
2013
20
Non-islet cell tumor hypoglycemia at the second recurrence of malignant solitary fibrous tumor in the retroperitoneum and pelvis: a case report. (22949904)
2012
21
Recurrent solitary fibrous tumor of the pleura with malignant transformation and non-islet cell tumor-induced hypoglycemia due to paraneoplastic overexpression and secretion of high-molecular-weight insulin-like growth Factor II. (23207122)
2012
22
Severe hypoglycemia with "Big"-IGF-2 oversecretion by a giant phyllode tumor of the breast: a rare case of non-islet cell tumor-induced hypoglycemia (NICTH). (22867750)
2012
23
Gastrointestinal stromal tumor of the pelvic soft tissue presenting with symptomatic hypoglycemia: A case report and brief review of current literature of non-islet cell tumor-induced hypoglycemia. (24371628)
2012
24
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. (23346016)
2012
25
Non-islet cell tumor hypoglycemia associated with uterine leiomyomata. (21550955)
2011
26
Pancreatic and peri-pancreatic lesions mimic pancreatic islet cell tumor in multidetector computed tomography. (21740785)
2011
27
Retrospective Review of Cross Sectional Imaging Findings of Pancreatic Non-functional Islet Cell Tumor (NFICT) and its Hepatic Metastases. (22043378)
2011
28
Diabetic ketoacidosis with concurrent pancreatitis, pancreatic I^ islet cell tumor, and adrenal disease in an obese ferret (Mustela putorius furo). (21838985)
2011
29
Metastatic pancreatic polypeptide-secreting islet cell tumor in a dog. (20698942)
2010
30
Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. (20660572)
2010
31
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. (19688373)
2010
32
Diffusion weighted MR imaging of pancreatic islet cell tumors. (19264435)
2010
33
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II. (20618739)
2010
34
Pancreatic islet cell tumor secreting insulin-like growth factor type-II in a dog. (19780935)
2009
35
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. (19657311)
2009
36
Non-islet cell tumor hypoglycemia. (19345293)
2009
37
Insulinoma with six islet cell tumors associated with severe hypoglycemia. (19525595)
2009
38
Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. (19567519)
2009
39
Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients. (18437902)
2008
40
Islet cell tumor of the pancreas: increasing diagnosis after instituting ultrasonography-guided fine needle aspiration. (18323274)
2008
41
Spontaneous pancreatic islet cell tumor in a black and white colobus monkey (Colobus guereza kikuyuensis). (18269522)
2008
42
Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. (18437091)
2008
43
Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin. (18278497)
2008
44
Hypoglycemia associated with the production of insulin-like growth factor II in a pancreatic islet cell tumor: a case report. (18490836)
2008
45
Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. (18825882)
2008
46
Generation and characterization of islet cell tumor in pTet-on/pTRE-SV40Tag double-transgenic mice model. (17697978)
2007
47
Differential diagnosis of non-functional islet cell tumor and pancreatic carcinoma with sonography. (17412543)
2007
48
Severe hypoglycemia induced by IGF-II producing non-islet cell tumor. (17603253)
2007
49
Non-islet cell tumor hypoglycemia in a patient with poorly differentiated thyroid cancer. (17274758)
2007
50
Solitary fibrous tumor associated with non-islet cell tumor hypoglycemia. (17588442)
2007

Variations for Islet Cell Tumor

About this section

Expression for genes affiliated with Islet Cell Tumor

About this section
Search GEO for disease gene expression data for Islet Cell Tumor.

Pathways for genes affiliated with Islet Cell Tumor

About this section

Pathways related to Islet Cell Tumor according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3IGF2, INS
29.1CALCA, PTHLH, VIP
3
Show member pathways
6.5CALCA, GAST, IGF2, INS, MEN1, PTHLH

GO Terms for genes affiliated with Islet Cell Tumor

About this section

Cellular components related to Islet Cell Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055768.0CALCA, GAST, IGF2, INS, PTHLH, SST
2extracellular spaceGO:00056157.3CALCA, CHGA, GAST, IGF2, INS, PTHLH

Biological processes related to Islet Cell Tumor according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.2CALCA, PTHLH
2negative regulation of vasodilationGO:004590810.2CHGA, INS
3positive regulation of vasodilationGO:00459099.9INS, VIP
4positive regulation of glycogen biosynthetic processGO:00457259.9IGF2, INS
5positive regulation of insulin receptor signaling pathwayGO:00466289.9IGF2, INS
6positive regulation of mitotic nuclear divisionGO:00458409.8IGF2, INS
7osteoblast developmentGO:00020769.8MEN1, PTHLH
8cell-cell signalingGO:00072679.7INS, PTHLH, SST
9cellular protein metabolic processGO:00442679.5CALCA, IGF2, INS
10regulation of protein localizationGO:00328809.4INS, VIP
11positive regulation of cell proliferationGO:00082849.0IGF2, INS, PTHLH, VIP

Molecular functions related to Islet Cell Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin receptor bindingGO:00051589.6IGF2, INS
2insulin-like growth factor receptor bindingGO:00051599.3IGF2, INS
3hormone activityGO:00051797.7CALCA, GAST, IGF2, INS, PTHLH, SST

Sources for Islet Cell Tumor

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet